A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: Report of a Japan Clinical Oncology Group trial (JCOG 9605)

British Journal of Cancer

Volumn 101, Issue 9, 2009, Pages 1549-1554

  Kunitoh, H ^a,i   Tamura, T ^a   Shibata, T ^b   Nakagawa, K ^c   Takeda, K ^d   Nishiwaki, Y ^e   Osaki, Y ^f   Noda, K ^g   Yokoyama, A ^h   Saijo, N ^c,e  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d OSAKA CITY GENERAL HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f ASAHIKAWA MEDICAL COLLEGE   (Japan)

^g KANAGAWA CANCER CENTER   (Japan)

^h Niigata Cancer Center   (Japan)

ⁱ MITSUI MEMORIAL HOSPITAL   (Japan)

Author keywords

Anthracycline; Chemotherapy; Dose dense; Granulocyte colony stimulating factor; Platinum; Thymoma

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; PLATINUM DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DISSEMINATED CANCER; DRUG EFFICACY; DRUG SAFETY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; INFECTION; JAPAN; LEUKOPENIA; LOCAL THERAPY; MALE; MULTIPLE CYCLE TREATMENT; MYASTHENIA GRAVIS; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; OXYGEN TENSION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; THYMOMA; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM STAGING; THYMOMA; THYMUS NEOPLASMS;

EID: 70350628966     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605347     Document Type: Article

References (33)

1. Berruti A, Borasio P, Gerbino A, Gorzegno G, Moschini T, Tampellini M, Ardissone F, Brizzi MP, Dolcetti A, Dogliotti L (1999) Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclopho-sphamide in locally advanced thymomas: a single institution experience. Br J Cancer 81: 841-845
2. Curran Jr WJ, Kornstein MJ, Brooks JJ, Turrisi 3rd AT (1988) Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol 6: 1722-1727
3. Eng TY, Fuller CD, Jagirdar J, Bains Y, Thomas Jr CR (2004) Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys 59: 654-664
4. Fornasiero A, Daniele O, Ghiotto C, Sartori F, Rea F, Piazza M, Fiore-Donati L, Morandi P, Aversa SM, Paccagnella A, Pappagallo GL, Fiorentino MV (1990) Chemotherapy of invasive thymoma. J Clin Oncol 8: 1419-1423
5. Freidlin B, Korn EL, Hunsberger S, Gray R, Saxman S, Zujewski JA (2007) Proposal for the use of progression-free survival in unblinded randomized trials. J Clin Oncol 25: 2122-2126
6. Fukuoka M, Masuda N, Negoro S, Matsui K, Yana T, Kudoh S, Kusunoki Y, Takada M, Kawahara M, Ogawara M, Kodama N, Kubota K, Furuse K (1997) CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 75: 306-309
7. Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K, Ariyoshi Y, Tamura T, Saijo N (1998) Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. J Clin Oncol 16: 2126-2132
8. Giaccone G (2005) Treatment of malignant thymoma. Curr Opin Oncol 17: 140-146
9. Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N (1996) Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 14: 814-820
10. Girard N, Mornex F, Van Houtte P, Cordier JF, van Schil P (2009) Thymoma: a focus on current therapeutic management. J Thorac Oncol 4: 119-126
11. Goldie JH, Coldman AJ (1983) Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep 67: 923-931
12. Goldie JH, Coldman AJ (1984) The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 44: 3643-3653
13. Hanna N, Gharpure VS, Abonour R, Cornetta K, Loehrer Sr PJ (2001) High-dose carboplatin with etoposide in patients with recurrent thymoma: the Indiana University experience. Bone Marrow Transplant 28: 435-438
14. Kim ES, Putnam JB, Komaki R, Walsh GL, Ro JY, Shin HJ, Truong M, Moon H, Swisher SG, Fossella FV, Khuri FR, Hong WK, Shin DM (2004) Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 44: 369-379
15. Lemma GL, Loehrer Sr PJ, Lee JW, Langer CJ, Tester WJ, Johnson DH (2008) A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic carcinoma: E1C99. J Clin Oncol 26(15S): abstract 8018
16. Levin L, Hryniuk WM (1987) Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5: 756-767
17. Loehrer Sr PJ, Chen M, Kim K, Aisner SC, Einhorn LH, Livingston R, Johnson D (1997) Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol 15: 3093-3099
18. Loehrer Sr PJ, Jiroutek M, Aisner S, Aisner J, Green M, Thomas Jr CR, Livingston R, Johnson DH (2001) Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer 91: 2010-2015
19. Loehrer Sr PJ, Kim K, Aisner SC, Livingston R, Einhorn LH, Johnson D, Blum R (1994) Cisplatin plus doxorubicin plus cyclopho-sphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 12: 1164-1168
20. Loehrer Sr PJ, Yiannoutsos CT, Dropcho S, Burns M, Helft P, Chiorean EG, Nelson RP (2006) A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 24(18S): abstract 7079
21. Lucchi M, Melfi F, Dini P, Basolo F, Viti A, Givigliano F, Angeletti CA, Mussi A (2006) Neoadjuvant chemotherapy for stage III and IVA thymomas: a single-institution experience with a long follow-up. J Thorac Oncol 1: 308-313
22. Masaoka A, Monden Y, Nakahara K, Tanioka T (1981) Follow-up study of thymomas with special reference to their clinical stages. Cancer 48: 2485-2492
23. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
24. Murray N (1987) The importance of dose and dose intensity in lung cancer chemotherapy. Semin Oncol 14: 20-28
25. Murray N, Shah A, Osoba D, Page R, Karsai H, Grafton C, Goddard K, Fairey R, Voss N (1991) Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol 9: 1632-1638
26. Ogawa K, Uno T, Toita T, Onishi H, Yoshida H, Kakinohana Y, Adachi G, Itami J, Ito H, Murayama S (2002) Postoperative radiotherapy for patients with completely resected thymoma: a multi-institutional, retrospective review of 103 patients. Cancer 94: 1405-1413
27. Okumura M, Ohta M, Tateyama H, Nakagawa K, Matsumura A, Maeda H, Tada H, Eimoto T, Matsuda H, Masaoka A (2002) The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 94: 624-632
28. Strobel P, Bauer A, Puppe B, Kraushaar T, Krein A, Toyka K, Gold R, Semik M, Kiefer R, Nix W, Schalke B, Muller-Hermelink HK, Marx A (2004) Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 22: 1501-1509
29. Thomas CR, Wright CD, Loehrer PJ (1999) Thymoma: state of the art. J Clin Oncol 17: 2280-2289
30. Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K, Narabayashi M, Fukutomi T, Kondo H, Shimoyama M, Suemasu K (1993) Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol 23: 250-257
31. Travis WB, Brambilla E, Muller-Hermelinck HK, Harris CC (2004) Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press: Lyon
32. Urgesi A, Monetti U, Rossi G, Ricardi U, Casadio C (1990) Role of radiation therapy in locally advanced thymoma. Radiother Oncol 19: 273-280
33. Yokoi K, Matsuguma H, Nakahara R, Kondo T, Kamiyama Y, Mori K, Miyazawa N (2007) Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. J Thorac Oncol 2: 73-78